Movement Alert｜ImmunityBio, Inc. Falls 5.2% in Regular Trading, Q3 Loss Widened and Revenue Missed Expectations

Market Focus11-11

On November 11, ImmunityBio, Inc. fell 5.2% in Regular Trading, trading at $6.7401 per share, with turnover of $90.3257 million.

The move was tied to continued pressure following the company’s latest third-quarter results, which came in below market expectations on both earnings and revenue.

ImmunityBio, Inc. reported a net loss of $0.18 per diluted share for the quarter, widening from a loss of $0.07 a year earlier and missing expectations for a $0.07 loss. Revenue rose to $48.841 million from $32.1 million a year earlier, but still missed the $59.25 million consensus. The company also disclosed clinical and registration progress for Anktiva, including regulatory advancement in bladder cancer and approval progress in Israel, but those updates did not offset investor concerns over the weaker financial performance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment